Goodwin
Wei Xu
- Deals
- 3
- Latest
- Apr 2026
- Most deals in
- Biotech
Firm
- Goodwin Law firm · 2026 · 3 deals
Often works with
- Daniel Karelitz 3 deals together
- Arman Oruc 3 deals together
- Felipe M. Heiderich 2 deals together
- Andrea Akinbola 2 deals together
- Artimus Cunningham 2 deals together
- Sarah Bock 2 deals together
- Kingsley L. Taft 2 deals together
- Jacob Osborn 2 deals together
Deals
Deals dated after 30 September 2026 are still being collected.
Columns
| Apr 2026 | Tubulis | EQT Life Sciences (LSP 7 fund) | Gilead Sciences | Acquisition | Legal adviser to Tubulis (target) | Announced | 3,150.0 | Biotech+2 | Gilead Sciences acquisition of Tubulis |
| Mar 2026 | Ouro Medicines | – | Gilead | Acquisition | Legal adviser to Ouro Medicines (target) | Announced | 1,675.0 | Biotech+1 | Gilead acquisition of Ouro Medicines |
| Feb 2026 | Orna Therapeutics | – | Eli Lilly and Company | Acquisition | Legal adviser to Orna Therapeutics (target) | Announced | 2,400.0 | Biotech+1 | Eli Lilly and Company acquisition of Orna Therapeutics |
Deals where Wei Xu is named on the firm's deal team, by the firm or the press.